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Direct-to-Consumer Advertising
(DTCA). DTCA refers to
advertisements that are directed to
patients, the final consumers of the
pharmaceutical product. In the U.S.,
the FDA permits three different
types of DTCA:
• Product-claim ads, which
mention the name of the drug,
outline its use, and describe the
risks and benefits, in addition to
discussing the medical condition it
treats;
• Help-seeking ads, which discuss
the medical condition but do not
mention a specific drug product; and
• Reminder ads, which provide
the name of the drug but do not
discuss its uses, risks, or benefits,
nor the medical condition it treats.
The purpose of this research is to
better understand the effectiveness
of Direct-to-Consumer Advertising
(DTCA) by examining consumer
perceptions of persuasive intent and
informativeness associated with
product-claim and help-seeking ads.
Contributions
1. Our findings help reconcile the
incompatible findings in the previous
literature, by distinguish between the
two types of DTCA – namely, product-
claim and help-seeking ads.
2. We assess DTCA effectiveness in
terms of behavioral intent (i.e.,
interest in learning more about and
desire to obtain care for the
advertised medical condition), rather
than using secondary data typically
associated with empirical studies
(e.g., prescription number or sales
revenue).
3. Our results can assist pharmaceutical
firms in better utilizing DTCA. Given
our results, practitioners may want to
consider the drawbacks of product-
claim DTCA – specifically, consumer
perceptions of high persuasive intent
and low informativeness. Conversely,
practitioners may want to recognize
help-seeking DTCA’s potential for
improving behavioral intent of the
advertised medical conditions through
its association with consumer
perceptions of low persuasive intent
and high informativeness.
Background
In the U.S., DTCA has grown rapidly 
since 1997 when the Food and Drug 
Administration liberated the 
regulations. In 2003, the U.S. 
pharmaceutical industry spent a total 
of $ 3.8 billion (USD) on DTCA 
delivered through television, radio, 
print, the Internet, and other media 
(Elliott, 2004), representing a 24.5% 
increase from the prior year (Toshi, 
2004). In 2005, industry-wide 
spending on DTCA reached $4.2 
billion (USD) (GAO, 2006), and it 
further increased to $5.6 billion (USD) 
in 2006 (Stremersch and Lemmens, 
2009). 
Currently, only the U.S. and New 
Zealand permit DTCA, but the rest of 
the world soon may follow suit, as 
several other countries (Europe, 
Australia, and Canada) are 
considering permitting DTCA (Auton, 
2006; Eagle and Chamberlain, 2004; 
Harker and Harker, 2007).
ResultsKey Concepts & Hypotheses
PERSUASIVE INTENT OF DTCA
the degree to which consumers infer the
intent of the ad to profit-based, convincing
consumers to seek prescriptions for the
advertised drug
H1. Product-claim (vs. help-seeking) ads a)
are associated with higher (lower)
persuasive intent and thus b) decrease
(increase) behavioral intent to seek
treatment for the advertised ailment.
INFORMATIVENESS OF DTCA
the degree to which the ad provides
consumers with facts about the advertised
disease and/or its treatments
H2. Help-seeking (vs. product-claim) ads a)
are associated with higher (lower)
informativeness and thus b) increase
(decrease) behavioral intent to seek
treatment for the advertised ailment.
H1a : Consumers perceived product-
claim DTCA as having higher
persuasive intent than help-seeking
DTCA (p = .0010).
H2a : Consumers perceived help-
seeking ads as more informative than
product-claim ads (p = .0053)
H1b and H2b: Help-seeking ads were
associated with higher concern about
the advertised disease (p = .0360)
and higher interest to learn more
about the advertised disease (p =
.0141)
Mediation Analysis
Methodology
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We conducted two pilot studies (to 
determine relevant symptoms and to 
simplify product-claim DTCA) and a main 
experiment.
DESIGN
2 × 2 between-subjects factorial design for 
the advertised ailments of migraine and 
clinical depression, varying the type of 
DTCA as product-claim or help-seeking.
STIMULI
Print ads for two medical conditions 
(migraine and clinical depression).  
SAMPLE
162 respondents, recruited at a mall in the 
northeastern U.S., voluntarily participated in 
the experiment. They ranged in age from 19 
to 40, with females comprising 49%. 
DEVELOPED SCALES
PERSUASIVE INTENT Cronbach’s alpha = .90
 THE ADVERTISER JUST WANTS TO SELL THE DRUG FOR [DISEASE].
 THE WAY THIS AD TRIES TO PERSUADE PEOPLE SEEMS ACCEPTABLE TO ME. 
(REVERSE-CODED)
 THE ADVERTISER TRIES TO PERSUADE THE AUDIENCE IN WAYS THAT I 
DON’T LIKE.
 THE ADVERTISER SEEMS TO BE TRYING TO INAPPROPRIATELY PERSUADE
THE CONSUMER AUDIENCE.
 THE ADVERTISER IS BEING PERSUASIVE WITHOUT BEING EXCESSIVELY
MANIPULATIVE. (REVERSE-CODED) 
INFORMATIVENESS Cronbach’s alpha = .93
 THE ADVERTISER WANTS TO PROVIDE INFORMATION ON [DISEASE].
 THE ADVERTISER WANTS TO RAISE PUBLIC AWARENESS ON [DISEASE]. 
 THE ADVERTISER CARES ABOUT PEOPLE’S HEALTH. 
 THE ADVERTISER WANTS TO EDUCATE THE PUBLIC ABOUT [DISEASE]. 
 THE ADVERTISER WANTS TO HELP THOSE WHO MAY HAVE [DISEASE]. 
